Evidence map›Paper›PMID 41800058›Full record

ArticleFrontiers in oncology2026

The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes.

Jindong Chen, Hao Wang, Conghui Shang, Zixu Fan, Ziyi Sheng, Tianqing Chu, Min Zhang, Liang Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Lung cancer metabolism: a dynamic and adaptive network.Cellular and molecular life sciences : CMLS · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jindong Chen *Department of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Hao Wang *Department of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Conghui Shang *Department of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zixu FanDepartment of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Ziyi ShengDepartment of Clinical Research Unit, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Tianqing ChuDepartment of Clinical Research Unit, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Min ZhangDepartment of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Liang ZhaoDepartment of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel pharmacological agent for diabetes and heart failure, may influence oncologic outcomes. Their role in advanced lung cancer patients with diabetes is unclear. Our study aims to evaluate SGLT2i's effects in this population. Methods: We performed a retrospective analysis of advanced lung cancer patients diagnosed with diabetes at our center between July 2020 and July 2024. The case cohort include patients who received SGLT2i, while the control cohort did not. The primary endpoint was overall mortality, and the secondary endpoint was a composite of cardiac events. Results: The cohort included 188 patients, with 94 cases and 94 controls. Over a median follow-up of 16 months, the use of SGLT2i was significantly associated with improved survival for advanced lung cancer with diabetes. (hazard ratio, (HR) 0.56; 95% CI 0.35-0.87, P = 0.009). The survival rate was lower in major adverse cardiovascular events (MACE) group than non-MACE group, however the differences were not statistically significant (HR 1.69; 95% CI 0.96- 2.97, P = 0.067). During follow-up, the incidence of MACE (24 cases in total, with new-onset atrial fibrillation/flutter being the most common) did not differ significantly between SGLT2i and control groups (11.7% vs. 13.8%; P = 0.662). Conclusions: In advanced lung cancer patients with diabetes, SGLT2i was associated with a lower all-cause mortality rate. Yet SGLT2i had insignificant impact on the incidence of MACE and the post-MACE survival.

Indexed as

advanced lung cancercardiotoxicitydiabetesoutcomeSGLT2i

Identifiers

PMID41800058
PMCPMC12962895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.